Search

Displaying results 1391 - 1400 of 5384 in total
  1. Drug

    Roxithromycin

    go.drugbank.com/drugs/DB00778
    ApprovedInvestigationalWithdrawn

    Roxithromycin exerts its antibacterial action by binding to the bacterial ribosome and interfering with bacterial protein synthesis.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  2. Drug

    Aminocaproic acid

    go.drugbank.com/drugs/DB00513
    ApprovedInvestigational

    An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.

  3. Drug

    Nintedanib

    go.drugbank.com/drugs/DB09079
    ApprovedInvestigational

    [L8453,L8459] It was first approved for use in the United States in 2014.

  4. Drug

    Aluminum chlorohydrex propylene glycol

    go.drugbank.com/drugs/DB11208
    Approved

    It is an antiperspirant active ingredient found in antiperspirant drug products for over-the-counter human use.

  5. Drug

    Oxyphenisatin acetate

    go.drugbank.com/drugs/DB14627
    ApprovedWithdrawn

    The FDA withdrew its approval for the use of oxyphenisatin acetate due to safety reasons.[L43942]

  6. Drug

    Phylloquinone

    go.drugbank.com/drugs/DB01022
    ApprovedInvestigational

    [L33319] Phylloquinone has been synthesized since at least 1939,[A234384] and was approved by the FDA prior to 1955.[L33389] … [A234264,A234195,A234259] It is indicated in the treatment of coagulation disorders due to faulty formation of coagulation factors II, VII, IX, and X caused by deficiency or interference in the activity

  7. Drug

    Caspofungin

    go.drugbank.com/drugs/DB00520
    ApprovedInvestigational

    It shows activity against infections with Aspergillus and Candida, and works by inhibiting β(1,3)-D-Glucan of the fungal cell wall. … Caspofungin (brand name Cancidas worldwide) is an antifungal drug and the first member of a new drug class called the echinocandins, as coined by Merck & Co., Inc.

    Categories: Antimycotics for Systemic Use, Antiinfectives for Systemic Use
  8. Drug

    Sutimlimab

    go.drugbank.com/drugs/DB14996
    ApprovedInvestigational

    [A245154] Notably, none of these agents are approved for use in the treatment of CAD. … In addition to non-pharmacological strategies, such as counseling patients to keep warm and the use of red blood cell transfusions, approximately 70% of patients require pharmacological treatment.

  9. Drug

    Sevabertinib

    go.drugbank.com/drugs/DB21667
    ApprovedInvestigational

    [L54638] It was granted accelerated approval by the FDA on November 19th, 2025.[L54608]

  10. Drug

    Siponimod

    go.drugbank.com/drugs/DB12371
    ApprovedInvestigational

    It was approved by the FDA on March 26, 2019 [L5792] and by Health Canada on February 20, 2020. … Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings.